David Guy Kirsch is an American oncologist currently the Barbara Levine University Professor at Duke University [1] and an Elected Fellow of the American Association for the Advancement of Science. [2]
He earned his M.D. and Ph.D. at Johns Hopkins University School of Medicine in 2000. [3]
His interests are in studying sarcomagenesis, cancer biology and radiation oncology. [2] His highest cited papers are "Conversion of Bcl-2 to a Bax-like death effector by caspases", [4] at 1332 times, and "Restoration of p53 function leads to tumour regression in vivo", [5] at 1320 times, according to Google Scholar. [6]
- Yoon, SW, Cramer, CK, Miles, DA, Reinsvold, MH, Joo, KM, Kirsch, DG, and Oldham, M. "A precision 3D conformal treatment technique in rats: Application to whole-brain radiotherapy with hippocampal avoidance." Medical physics 44, no. 11 (November 2017): 6008–6017.
- Dodd, RD, Lee, C-L, Overton, T, Huang, W, Eward, WC, Luo, L, Ma, Y, Ingram, DR, Torres, KE, Cardona, DM, Lazar, AJ, and Kirsch, DG. "NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response." Cancer research 77, no. 16 (August 2017): 4486–4497.
- Huang, J, Chen, M, Whitley, MJ, Kuo, H-C, Xu, ES, Walens, A, Mowery, YM, Van Mater, D, Eward, WC, Cardona, DM, Luo, L, Ma, Y, Lopez, OM, Nelson, CE, Robinson-Hamm, JN, Reddy, A, Dave, SS, Gersbach, CA, Dodd, RD, and Kirsch, DG. "Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature communications 8 (July 10, 2017): 15999-.
- Castle, KD, Chen, M, Wisdom, AJ, and Kirsch, DG. "Genetically engineered mouse models for studying radiation biology." Translational Cancer Research 6, no. S5 (July 2017): S900-S913.
- McConnell, AM, Yao, C, Yeckes, AR, Wang, Y, Selvaggio, AS, Tang, J, Kirsch, DG, and Stripp, BR. "p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway." Cell reports 17, no. 9 (November 2016): 2173–2182.
- ^ "Kirsch Lab". duke.edu. Archived from the original on December 10, 2017. Retrieved December 20, 2017.
- ^ a b "Three Faculty Elected Fellows AAAS". duke.edu. November 21, 2017. Archived from the original on December 20, 2017. Retrieved December 20, 2017.
- ^ "David Kirsch". duke.edu. Archived from the original on February 5, 2018. Retrieved December 20, 2017.
- ^ Emily H-Y Cheng, David G Kirsch, Rollie J Clem, Rajani Ravi, Michael B Kastan, Atul Bedi, Kazuyoshi Ueno, J Marie Hardwick. Conversion of Bcl-2 to a Bax-like death effector by caspases. 278:5345. Science. 1997
- ^ Andrea Ventura, David G Kirsch, Margaret E McLaughlin, David A Tuveson, Jan Grimm, Laura Lintault, Jamie Newman, Elizabeth E Reczek, Ralph Weissleder, Tyler Jacks. Restoration of p53 function leads to tumour regression in vivo. 445:7128. 661-665. Nature. 2007
- ^ "David Kirsch". Archived from the original on February 15, 2023. Retrieved December 20, 2017.
| Authority control databases: Academics |
|---|
David Guy Kirsch is an American oncologist currently the Barbara Levine University Professor at Duke University [1] and an Elected Fellow of the American Association for the Advancement of Science. [2]
He earned his M.D. and Ph.D. at Johns Hopkins University School of Medicine in 2000. [3]
His interests are in studying sarcomagenesis, cancer biology and radiation oncology. [2] His highest cited papers are "Conversion of Bcl-2 to a Bax-like death effector by caspases", [4] at 1332 times, and "Restoration of p53 function leads to tumour regression in vivo", [5] at 1320 times, according to Google Scholar. [6]
- Yoon, SW, Cramer, CK, Miles, DA, Reinsvold, MH, Joo, KM, Kirsch, DG, and Oldham, M. "A precision 3D conformal treatment technique in rats: Application to whole-brain radiotherapy with hippocampal avoidance." Medical physics 44, no. 11 (November 2017): 6008–6017.
- Dodd, RD, Lee, C-L, Overton, T, Huang, W, Eward, WC, Luo, L, Ma, Y, Ingram, DR, Torres, KE, Cardona, DM, Lazar, AJ, and Kirsch, DG. "NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response." Cancer research 77, no. 16 (August 2017): 4486–4497.
- Huang, J, Chen, M, Whitley, MJ, Kuo, H-C, Xu, ES, Walens, A, Mowery, YM, Van Mater, D, Eward, WC, Cardona, DM, Luo, L, Ma, Y, Lopez, OM, Nelson, CE, Robinson-Hamm, JN, Reddy, A, Dave, SS, Gersbach, CA, Dodd, RD, and Kirsch, DG. "Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature communications 8 (July 10, 2017): 15999-.
- Castle, KD, Chen, M, Wisdom, AJ, and Kirsch, DG. "Genetically engineered mouse models for studying radiation biology." Translational Cancer Research 6, no. S5 (July 2017): S900-S913.
- McConnell, AM, Yao, C, Yeckes, AR, Wang, Y, Selvaggio, AS, Tang, J, Kirsch, DG, and Stripp, BR. "p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway." Cell reports 17, no. 9 (November 2016): 2173–2182.
- ^ "Kirsch Lab". duke.edu. Archived from the original on December 10, 2017. Retrieved December 20, 2017.
- ^ a b "Three Faculty Elected Fellows AAAS". duke.edu. November 21, 2017. Archived from the original on December 20, 2017. Retrieved December 20, 2017.
- ^ "David Kirsch". duke.edu. Archived from the original on February 5, 2018. Retrieved December 20, 2017.
- ^ Emily H-Y Cheng, David G Kirsch, Rollie J Clem, Rajani Ravi, Michael B Kastan, Atul Bedi, Kazuyoshi Ueno, J Marie Hardwick. Conversion of Bcl-2 to a Bax-like death effector by caspases. 278:5345. Science. 1997
- ^ Andrea Ventura, David G Kirsch, Margaret E McLaughlin, David A Tuveson, Jan Grimm, Laura Lintault, Jamie Newman, Elizabeth E Reczek, Ralph Weissleder, Tyler Jacks. Restoration of p53 function leads to tumour regression in vivo. 445:7128. 661-665. Nature. 2007
- ^ "David Kirsch". Archived from the original on February 15, 2023. Retrieved December 20, 2017.
| Authority control databases: Academics |
|---|